Orthocell Release: Positive Data On Ortho-ATI Tendon Treatment Presented At Key International Conference

• Orthocell presents positive 3-5 year data for Ortho-ATITM degenerate tendon treatment

• Data shows significant outcomes including reduced pain and increased functionality

• Results presented at conference of leading international musculoskeletal experts

Perth, Australia; 12 May 2015: Regenerative medicine company Orthocell Limited is pleased to announce positive 3-5 year data from a study of its tendon cell treatment for tennis elbow has been presented at the International Cartilage Repair Society annual scientific meeting.

The data shows Orthocell’s Ortho-ATITM therapy significantly improved the clinical outcome of patients with long term tennis elbow degeneration, showing reduced pain and increased functionality out to five years.

The International Cartilage Repair Society is a leading international conference of musculoskeletal experts and Orthocell presented at its annual scientific meeting held in Chicago, USA. Orthocell’s Chief Scientific Officer, Professor Ming Hao Zheng, from the University of Western Australia’s School of Surgery and Centre for Orthopaedic Research, presented the study.

Orthocell Managing Director, Mr Paul Anderson, said: “Health professionals around the world are becoming more aware of Ortho-ATITM and its long-term effectiveness in treating musculoskeletal conditions such as tennis elbow and other problematic tendons. Acceptance of this data at international meetings of this standard is further validation of the relevance of this exciting new approach to this difficult clinical challenge.”

He said Orthocell and its world-leading stem cell regeneration therapies are providing significant relief to patients.

“As the population ages, mobility becomes a significant issue and degenerate tendon conditions become more prevalent, so doctors and patients are seeking out proven treatments to increase patients’ mobility and quality of life.”

The pilot study investigated the effect of Ortho-ATITM in 17 patients who were all assessed by an independent therapist out to five years, representing one of the longest data sets in cell therapies today.

Patients demonstrated an incredible 207% increase in their grip strength abilities and were ‘highly satisfied’ with the outcome of their treatment.

Transparency Market Research estimate that the US, Europe and Japan markets for tennis elbow treatment is estimated to be worth US$700 million in 2015.

For more information, please contact:

General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: (08) 9360 2888
E: paulanderson@orthocell.com.au

Investor relations
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
E: rwilson@buchanwe.com.au

Media enquiries
Gavin Lower
Buchan Consulting
P: (03) 8866 1215 / 0414 796 726
E: glower@buchanwe.com.au

About Orthocell Limited

Orthocell is a commercial-stage, regenerative medicine company focused on regenerating mobility for patients and our ageing population by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) and Autologous Chondrocyte Implantation (Ortho-ACI™), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

Help employers find you! Check out all the jobs and post your resume.

Back to news